Eric Woolf

4.3k total citations
96 papers, 2.7k citations indexed

About

Eric Woolf is a scholar working on Pharmacology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Eric Woolf has authored 96 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pharmacology, 27 papers in Molecular Biology and 22 papers in Infectious Diseases. Recurrent topics in Eric Woolf's work include HIV/AIDS drug development and treatment (21 papers), Biosimilars and Bioanalytical Methods (19 papers) and Inflammatory mediators and NSAID effects (17 papers). Eric Woolf is often cited by papers focused on HIV/AIDS drug development and treatment (21 papers), Biosimilars and Bioanalytical Methods (19 papers) and Inflammatory mediators and NSAID effects (17 papers). Eric Woolf collaborates with scholars based in United States, United Kingdom and Belgium. Eric Woolf's co-authors include B.K. Matuszewski, I. Fu, Yang Xu, William Nowatzke, Catherine Z. Matthews, Mark J. Rose, Nancy Agrawal, Patrick T. Vallano, Wei Zeng and K. C. Yeh and has published in prestigious journals such as Analytical Chemistry, Antimicrobial Agents and Chemotherapy and Journal of Bone and Mineral Research.

In The Last Decade

Eric Woolf

94 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric Woolf United States	32	785	572	566	499	491	96	2.7k
Iain J. McGilveray Canada	15	847 1.1×	789 1.4×	524 0.9×	426 0.9×	610 1.2×	29	3.3k
Mohammed Jemal United States	34	427 0.5×	1.4k 2.4×	1.6k 2.8×	522 1.0×	707 1.4×	134	3.8k
James D. Hulse United States	18	410 0.5×	521 0.9×	314 0.6×	269 0.5×	311 0.6×	31	2.2k
Howard Hill United Kingdom	13	380 0.5×	688 1.2×	297 0.5×	581 1.2×	323 0.7×	46	2.2k
Mark L. Powell United States	15	400 0.5×	483 0.8×	437 0.8×	281 0.6×	387 0.8×	34	1.9k
Gordon McKay Canada	17	486 0.6×	436 0.8×	266 0.5×	268 0.5×	266 0.5×	23	2.1k
Tawakol A. El‐Shourbagy United States	21	195 0.2×	419 0.7×	570 1.0×	205 0.4×	434 0.9×	47	1.6k
Alfred Tonelli United States	12	434 0.6×	477 0.8×	218 0.4×	286 0.6×	261 0.5×	25	2.0k
Nuggehally R. Srinivas India	32	654 0.8×	903 1.6×	663 1.2×	219 0.4×	626 1.3×	254	3.4k
Yngve Bergqvist Sweden	28	552 0.7×	263 0.5×	276 0.5×	302 0.6×	279 0.6×	100	2.4k

Countries citing papers authored by Eric Woolf

Since Specialization

Citations

This map shows the geographic impact of Eric Woolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Woolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Woolf more than expected).

Fields of papers citing papers by Eric Woolf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Woolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Woolf. The network helps show where Eric Woolf may publish in the future.

Co-authorship network of co-authors of Eric Woolf

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Woolf. A scholar is included among the top collaborators of Eric Woolf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Woolf. Eric Woolf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wickremsinhe, Enaksha, et al.. (2024). ICH M10 Bioanalytical Method Validation Guideline-1 year Later. The AAPS Journal. 26(5). 103–103. 9 indexed citations

Mitra‐Kaushik, Shibani, et al.. (2023). Cloud security in a bioanalytical world: considerations for use of third-party cloud services for bioanalysis. Bioanalysis. 15(24). 1461–1468. 1 indexed citations

Anderson, Melanie, Marissa F. Dockendorf, Ian McIntosh, et al.. (2022). An Investigation of Instability in Dried Blood Spot Samples for Pharmacokinetic Sampling in Phase 3 Trials of Verubecestat. The AAPS Journal. 24(3). 52–52. 3 indexed citations

Keller, Stephen, Jorge Quiroz, Enaksha Wickremsinhe, et al.. (2021). The Effectiveness of Quality Control Samples in Pharmaceutical Bioanalysis. Bioanalysis. 13(3). 135–145.

Zhang, Ying, Simon Letarte, Rong‐Sheng Yang, et al.. (2020). A Tiered Approach for Characterization to Ensure Quality, Reproducibility, and Long-Term Stability of Critical Reagents in Regulated Bioanalysis to Support PK/ADA/NAb Assays for Biologics and Vaccines Programs. ACS Pharmacology & Translational Science. 3(6). 1310–1317. 6 indexed citations

Xu, Yang, Melanie Anderson, Ming Wang, et al.. (2018). Extractability-mediated stability bias and hematocrit impact: High extraction recovery is critical to feasibility of volumetric adsorptive microsampling (VAMS) in regulated bioanalysis. Journal of Pharmaceutical and Biomedical Analysis. 156. 58–66. 68 indexed citations

Breidinger, Sheila, Richard C. Simpson, Eric Mangin, & Eric Woolf. (2015). Determination of suvorexant in human plasma using 96-well liquid–liquid extraction and HPLC with tandem mass spectrometric detection. Journal of Chromatography B. 1002. 254–259. 19 indexed citations

Xu, Yang, Marita Prohn, Xiaoyan Cai, et al.. (2014). Direct Comparison of Radioimmunoassay and LC–MS/MS for PK Assessment of Insulin Glargine in Clinical Development. Bioanalysis. 6(24). 3311–3323. 12 indexed citations

Kall, Morten A., et al.. (2007). Development and validation of a selective and sensitive bioanalytical procedure for the quantitative determination of gaboxadol in human plasma employing mixed mode solid phase extraction and hydrophilic interaction liquid chromatography with tandem mass spectroscopic detection. Journal of Chromatography B. 858(1-2). 168–176. 19 indexed citations

10.

Vallano, Patrick T., Eric Woolf, & B.K. Matuszewski. (2005). Determination of an investigational HIV integrase inhibitor in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. Journal of Chromatography B. 820(1). 69–76. 3 indexed citations

11.

Xu, Yang, Lihong Du, Mark J. Rose, et al.. (2005). Concerns in the development of an assay for determination of a highly conjugated adsorption-prone compound in human urine. Journal of Chromatography B. 818(2). 241–248. 31 indexed citations

12.

Vallano, Patrick T., Sarah Shugarts, Eric Woolf, & B.K. Matuszewski. (2004). Elimination of autosampler carryover in a bioanalytical HPLC-MS/MS method: a case study. Journal of Pharmaceutical and Biomedical Analysis. 36(5). 1073–1078. 24 indexed citations

13.

Agrawal, Nancy, Catherine Z. Matthews, Ralph S. Mazenko, et al.. (2004). The Effects of Modifying In Vivo Cytochrome P450 3A (CYP3A) Activity on Etoricoxib Pharmacokinetics and of Etoricoxib Administration on CYP3A Activity. The Journal of Clinical Pharmacology. 44(10). 1125–1131. 19 indexed citations

14.

Matthews, Catherine Z., et al.. (2004). Isolation and structural characterization of the photolysis products of etoricoxib.. PubMed. 59(12). 913–9. 7 indexed citations

15.

Agrawal, Nancy, Catherine Z. Matthews, Ralph S. Mazenko, et al.. (2003). Pharmacokinetics of Etoricoxib in Patients with Renal Impairment. The Journal of Clinical Pharmacology. 44(1). 48–58. 32 indexed citations

16.

Rodrigues, A. David, Rita A. Halpin, Leslie A. Geer, et al.. (2003). Absorption, Metabolism, and Excretion of Etoricoxib, a Potent and Selective Cyclooxygenase-2 Inhibitor, in Healthy Male Volunteers. Drug Metabolism and Disposition. 31(2). 224–232. 64 indexed citations

17.

Mazenko, Ralph S., et al.. (2001). SAMPLE PREPARATION VIA SOLID PHASE EXTRACTION IN THE 96-WELL FORMAT FOR HPLC/UV DETECTION-BASED BIOFLUID ASSAYS. APPLICATION TO THE DETERMINATION OF A NOVEL CYCLOOXYGENASE II INHIBITOR IN HUMAN PLASMA AND URINE. Journal of Liquid Chromatography & Related Technologies. 24(17). 2601–2614. 3 indexed citations

18.

Rose, Mark J., et al.. (1999). Determination of L-756 423, a novel HIV protease inhibitor, in human plasma and urine using high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B Biomedical Sciences and Applications. 732(2). 425–435. 4 indexed citations

19.

Woolf, Eric, I. Fu, & B.K. Matuszewski. (1999). Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection. Journal of Chromatography B Biomedical Sciences and Applications. 730(2). 221–227. 50 indexed citations

20.

Balani, Suresh K., Eric Woolf, Marc G. Sturgill, et al.. (1996). Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.. Drug Metabolism and Disposition. 24(12). 1389–1394. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact